https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Reconsidering Later-Line Therapies in CML Management

Reconsidering Later-Line Therapies in CML Management

An expert discusses how traditionally later-line therapies such as ponatinib and asciminib are now being reconsidered for earlier use, with asciminib approved for frontline treatment and ponatinib potentially used as second-line therapy for patients with specific mutations or comorbidities.

administrator

Related Articles